"Sunitinib refractory GIST" trang 1 - tải miễn phí từ tailieunhanh
Tổng hợp 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid làm tác nhân điều chế thuốc sunitinib chống ung thư

Tổng hợp 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid làm tác nhân điều chế thuốc sunitinib chống ung thư
5    90    0
Tóm tắt Luận văn Thạc sĩ Khoa học: Tổng hợp 5-formyl-2,4-dimethyl-1Hpyrrole-3-carboxylic acid để làm tác nhân điều chế thuốc sunitinib chống ung thư

Tóm tắt Luận văn Thạc sĩ Khoa học: Tổng hợp 5-formyl-2,4-dimethyl-1Hpyrrole-3-carboxylic acid để làm tác nhân điều chế thuốc sunitinib chống ung thư
30    58    0
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
7    60    0
Luận văn Thạc sĩ Khoa học: Tổng hợp 5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic acid làm các tác nhân điều chế thuốc sunitinib chống ung thư

Luận văn Thạc sĩ Khoa học: Tổng hợp 5-Formyl-2,4-Dimethyl-1H-Pyrrole-3-Carboxylic acid làm các tác nhân điều chế thuốc sunitinib chống ung thư
63    59    1
Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: A proof-of-concept study

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: A proof-of-concept study
13    29    1
Efficacy and safety analysis of TACE+sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: A retrospective study

Efficacy and safety analysis of TACE+sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: A retrospective study
11    5    1
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: Results of matching-adjusted indirect comparison analyses

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: Results of matching-adjusted indirect comparison analyses
12    76    1
Báo cáo sinh học:

Báo cáo sinh học: "Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib"
14    37    0
báo cáo hóa học:

báo cáo hóa học:" Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib"
14    46    0
báo cáo khoa học:

báo cáo khoa học: "Metastatic collecting duct carcinoma of the kidney treated with sunitinib"
3    29    0
Báo cáo khoa học:

Báo cáo khoa học: "Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report)"
4    40    0
Báo cáo khoa học:

Báo cáo khoa học: "Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment"
3    39    0
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
8    72    0
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: Pooled subgroup analysis from the randomized, COMPARZ studies

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: Pooled subgroup analysis from the randomized, COMPARZ studies
8    56    0
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: A metaanalysis

Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: A metaanalysis
12    62    0
Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: A multicentre case series

Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: A multicentre case series
7    68    1
Pneumatosis cystoides intestinalis associated with sunitinib and a literature review

Pneumatosis cystoides intestinalis associated with sunitinib and a literature review
5    25    1
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
12    77    1
Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
10    71    1
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors
10    57    1